AR032622A1 - Compuestos de 4-amino-azepan-3-ona, composiciones farmaceuticas que los comprenden, intermediarios utiles en la sintesis de tales compuestos, procedimiento para la sintesis de dichos compuestos, y uso de tales compuestos en la fabricacion de medicamentos - Google Patents

Compuestos de 4-amino-azepan-3-ona, composiciones farmaceuticas que los comprenden, intermediarios utiles en la sintesis de tales compuestos, procedimiento para la sintesis de dichos compuestos, y uso de tales compuestos en la fabricacion de medicamentos

Info

Publication number
AR032622A1
AR032622A1 ARP010102840A ARP010102840A AR032622A1 AR 032622 A1 AR032622 A1 AR 032622A1 AR P010102840 A ARP010102840 A AR P010102840A AR P010102840 A ARP010102840 A AR P010102840A AR 032622 A1 AR032622 A1 AR 032622A1
Authority
AR
Argentina
Prior art keywords
compounds
alkyl
synthesis
het
azepan
Prior art date
Application number
ARP010102840A
Other languages
English (en)
Spanish (es)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR032622A1 publication Critical patent/AR032622A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ARP010102840A 2000-06-14 2001-06-14 Compuestos de 4-amino-azepan-3-ona, composiciones farmaceuticas que los comprenden, intermediarios utiles en la sintesis de tales compuestos, procedimiento para la sintesis de dichos compuestos, y uso de tales compuestos en la fabricacion de medicamentos AR032622A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59384500A 2000-06-14 2000-06-14

Publications (1)

Publication Number Publication Date
AR032622A1 true AR032622A1 (es) 2003-11-19

Family

ID=24376433

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010102840A AR032622A1 (es) 2000-06-14 2001-06-14 Compuestos de 4-amino-azepan-3-ona, composiciones farmaceuticas que los comprenden, intermediarios utiles en la sintesis de tales compuestos, procedimiento para la sintesis de dichos compuestos, y uso de tales compuestos en la fabricacion de medicamentos

Country Status (25)

Country Link
EP (1) EP1307204A4 (sk)
JP (1) JP2004503502A (sk)
KR (1) KR20030008220A (sk)
CN (1) CN1444481A (sk)
AP (1) AP2002002671A0 (sk)
AR (1) AR032622A1 (sk)
AU (1) AU2001268407A1 (sk)
BG (1) BG107327A (sk)
BR (1) BR0111693A (sk)
CA (1) CA2412353A1 (sk)
CZ (1) CZ20024086A3 (sk)
EA (1) EA200300018A1 (sk)
EC (1) ECSP024388A (sk)
HU (1) HUP0301231A2 (sk)
IL (1) IL153421A0 (sk)
MA (1) MA25758A1 (sk)
MX (1) MXPA02012442A (sk)
NO (1) NO20025786L (sk)
NZ (1) NZ522965A (sk)
OA (1) OA12288A (sk)
PE (1) PE20011374A1 (sk)
PL (1) PL360508A1 (sk)
SK (1) SK17592002A3 (sk)
WO (1) WO2001095911A1 (sk)
ZA (1) ZA200209808B (sk)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003513926A (ja) * 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
WO2001034159A1 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
CN1635903A (zh) * 2000-11-22 2005-07-06 史密丝克莱恩比彻姆公司 蛋白酶抑制剂
US7709510B2 (en) 2001-02-20 2010-05-04 Chugai Seiyaku Kabushiki Kaisha Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
HU229431B1 (en) 2001-02-20 2013-12-30 Chugai Pharmaceutical Co Ltd Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
EP1401453A4 (en) * 2001-05-17 2005-04-06 Smithkline Beecham Corp PROTEASE INHIBITORS
JP4648317B2 (ja) 2003-08-01 2011-03-09 中外製薬株式会社 マロニル−ＣｏＡデカルボキシラーゼ阻害剤として有用なピペリジン化合物
US7696365B2 (en) 2003-08-01 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors
WO2005037258A2 (en) 2003-08-01 2005-04-28 Chugai Seiyaku Kabushiki Kaisha Cyanoguanidine-based azole compounds useful as malonyl-coa decarboxylase inhibitors
WO2009087379A2 (en) 2008-01-09 2009-07-16 Amura Therapeutics Limited Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases
CN103275070A (zh) * 2013-05-10 2013-09-04 郑彪 调节单核细胞增殖的四环化合物及其应用
US9427441B2 (en) 2014-02-19 2016-08-30 Indiana University Research And Technology Corporation Targeting primary cilia to treat glaucoma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2285A1 (fr) * 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.
NZ511710A (en) * 1998-12-23 2003-12-19 Smithkline Beecham Corp 4-Amino-azepan-3-one derivatives useful as protease inhibitors
JP2003513956A (ja) * 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
JP2003513926A (ja) * 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
WO2002017924A1 (en) * 2000-09-01 2002-03-07 Smithkline Beecham Corporation Method of treatment
CN1635903A (zh) * 2000-11-22 2005-07-06 史密丝克莱恩比彻姆公司 蛋白酶抑制剂
EP1401453A4 (en) * 2001-05-17 2005-04-06 Smithkline Beecham Corp PROTEASE INHIBITORS

Also Published As

Publication number Publication date
NZ522965A (en) 2004-06-25
AP2002002671A0 (en) 2002-12-31
JP2004503502A (ja) 2004-02-05
WO2001095911A1 (en) 2001-12-20
OA12288A (en) 2003-12-12
HUP0301231A2 (hu) 2003-08-28
NO20025786D0 (no) 2002-12-02
EA200300018A1 (ru) 2003-06-26
CA2412353A1 (en) 2001-12-20
NO20025786L (no) 2003-02-12
EP1307204A4 (en) 2004-06-02
PL360508A1 (en) 2004-09-06
SK17592002A3 (sk) 2003-05-02
KR20030008220A (ko) 2003-01-24
PE20011374A1 (es) 2002-04-07
MXPA02012442A (es) 2003-04-25
CN1444481A (zh) 2003-09-24
CZ20024086A3 (cs) 2003-05-14
AU2001268407A1 (en) 2001-12-24
BG107327A (bg) 2003-07-31
ZA200209808B (en) 2004-07-09
ECSP024388A (es) 2003-02-06
EP1307204A1 (en) 2003-05-07
BR0111693A (pt) 2004-04-06
MA25758A1 (fr) 2003-04-01
IL153421A0 (en) 2003-07-06

Similar Documents

Publication Publication Date Title
AR032877A1 (es) Inhibidores alquil c(1-6)-4-amino-azepan-3-onicos de proteasas, composiciones farmaceuticas que los comprenden, intermediarios utiles en la preparacion de tales compuestos, procedimiento para la sintesis de dichos inhibidores, y uso de dichos inhibidores en la fabricacion de medicamentos
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
ECSP034732A (es) Derivado de fenetanolamina para el tratamiento de enfermedades respiratorias
DOP2001000271A (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes antiinflamatorios y analgésicos.
BR0111263A (pt) Derivados de 2-aminocarbonil-9h-purina
MEP9509A (en) Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof
ECSP066383A (es) Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias
PA8547701A1 (es) Nucleosidos 4 substituidos.
AR035792A1 (es) Compuestos de n-(4-quinazolinil)-n-(1h-indazol-5-il) amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y metodo para prepararlo
SE0104332D0 (sv) Therapeutic agents
AR034268A1 (es) Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion
HUP0303084A2 (hu) Gyulladásgátló hatású 17béta-karbotioát-17alfa-arilkarboniloxiloxi androsztán-származékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
DE60132309D1 (de) Amin-derivate zur behandlung von apoptosis
PT1263724E (pt) Novos compostos
PA8529501A1 (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa -7."
HUP0402225A2 (hu) Makrolid-vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ES2123039T3 (es) Nuevas 3-(hidroxi-bencilidenil)-indolin-2-onas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
AR003440A1 (es) Nuevos derivados de aminoacidos, formulacion farmaceutica que los contiene, uso de dichos derivados para preparar medicamentos y procedimiento para la preparacion de dichos derivados.
AR029150A1 (es) Un derivado de piperidina, su empleo, un procedimiento para prepararlo y una composicin farmaceutica que lo comprende.
AR032622A1 (es) Compuestos de 4-amino-azepan-3-ona, composiciones farmaceuticas que los comprenden, intermediarios utiles en la sintesis de tales compuestos, procedimiento para la sintesis de dichos compuestos, y uso de tales compuestos en la fabricacion de medicamentos
CR7956A (es) Oxazolidinonas de indolona antibacterial intermedios para su preparacion y composiciones farmaceuticas que contienen los mismos
PA8495101A1 (es) Derivados de 13-metileritromicina
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister

Legal Events

Date Code Title Description
FA Abandonment or withdrawal